Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04116112 · ClinicalTrials.gov registry record · Phase 2
Blood Pressure After Endovascular Stroke Therapy-II
A Phase 2 study of Acute Stroke and Endovascular Thrombectomy, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT04116112: Completed Phase 2 study of Acute Stroke and Endovascular Thrombectomy, sponsored by University of Cincinnati.
NCT04116112 is a Phase 2 study of Acute Stroke and Endovascular Thrombectomy that has completed, run by University of Cincinnati. The registered enrollment target is 120 participants, below the 6,114-participant average among 10 other Acute Stroke trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04116112, a Phase 2 study of Acute Stroke and Endovascular Thrombectomy, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the safety of lowering blood pressure in acute stroke patients that are successfully treated with a mechanical thrombectomy procedure. The investogators will evaluate the hypothesis that lower blood pressure management strategies do not result in larger volume of stroke or worse 3-month clinical outcome in these patients.
Primary Outcome
Infarct volume on diffusion-weighted MRI (or CT if MRI cannot be obtained) at 36 (+/-12) hrs after treatment initiation, adjusted for the baseline CT perfusion core infract volume.
Conditions Studied
Interventions
- DRUG Labetalol
- DRUG Hydralazine
- DRUG Nicardipine
Study Locations (3)
Connecticut
- Hartford Healthcare - Hartford
Ohio
- University of Cincinnati - Cincinnati
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-01-17 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
What the finished NCT04116112 record still lists
NCT04116112 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 6,114-participant average among 10 other Acute Stroke trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Acute Stroke appearing as the primary indexed condition, and to 3 interventions - of which Labetalol is the first listed.
NCT04116112 reports a single indexed study location in Connecticut, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04116112 about?
NCT04116112 is a clinical study titled "Blood Pressure After Endovascular Stroke Therapy-II". The purpose of this study is to assess the safety of lowering blood pressure in acute stroke patients that are successfully treated with a mechanical thrombectomy procedure. The investogators will evaluate the hypothesis that lower blood pressure management strategies do not result in larger volume ...
What is the current status of trial NCT04116112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2020-01-17. Estimated completion is 2022-12-15.
What conditions does trial NCT04116112 study?
This clinical trial studies the following conditions: Acute Stroke, Endovascular Thrombectomy.
What interventions are being tested in trial NCT04116112?
The interventions under investigation include: Labetalol (DRUG), Hydralazine (DRUG), Nicardipine (DRUG).
Who is sponsoring clinical trial NCT04116112?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04116112 being conducted?
This trial has 3 study locations across Connecticut, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04116112's enrollment target sits among peer trials
120 4th of 10 higher than 7 of 10 other Acute Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
RECRUITING · Phase 2
-
Robot Assisted Upper Limb Neuro-Rehabilitation
COMPLETED · Phase 2
-
Beta-hCG + Erythropoietin in Acute Stroke
COMPLETED · Phase 2
-
Ischemic Conditioning During Air tRansport Save penUmbral Tissue
RECRUITING · NA
-
Stroke Recovery Initiative - Registry for Stroke Research Studies
RECRUITING
-
SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI